Nile Therapeutics appoints Darlene Horton as Chief Medical Officer
Biopharmaceutical company Nile Therapeutics, Inc has said it has appointed Darlene Horton as its Chief Medical Officer.
Mr. Horton earlier held the position of Chief Medical Officer at Itero Biopharmaceuticals, a venture-backed company which was involved in developing and out-licensing a bio similar protein therapeutic. Before joining Itero, Dr. Horton also served as Senior Vice President, Clinical Research at Scios, Inc, a Johnson & Johnson company.
Darelene Horton was also the clinical lead for Natrecor, a commercial product indicated to treat acute heart failure, during her 12 year tenure at Scios. She also led the program to the FDA’s cardiovascular and renal advisory committee prior to successful approval.
Joshua Kazam, CEO of Nile said, “We are excited for Dr Horton to join the Nile team.” Mr. Kazam also said, “We believe Dr Horton’s proven track record in the development of cardiovascular therapies will be invaluable to Nile as we push forward the cenderitide post-acute heart failure problem.”
Nile Therapeutics, Inc is a clinical stage biopharmaceutical company involved in developing innovative products to treat cardiovascular disease, within an initial focus on heart failure. The company is developing its lead product candidate, cenderitide to treat the patients following the admission for acutely decompensated heart failure, an acute exacerbation of heart failure.
